poisar

Stocks · News reference

Labcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029

BenzingaBenzinga Newsdesk

On September 21, 2026, the Centers for Medicare & Medicaid Services ("CMS") released preliminary Clinical Laboratory Fee Schedule payment rates applicable from 2027 through 2029 pursuant to the Protecting

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncResearchandmarkets.Com

    Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments

    The global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.

  2. The Motley FoolRich Smith

    Why Labcorp Holdings Stock Dropped Today

    Labcorp Holdings stock fell 3.3% after the Centers for Medicare & Medicaid Services announced plans to reduce lab testing reimbursement rates by 15% starting next year, with potential additional cuts through 2029. Since CMS accounts for approximately 8% of Labcorp's revenue, a full 15% reduction would decrease annual revenue by 1.2%, with a worst-case scenario of 3.6% reduction if cuts continue through 2029. The stock's decline appears to have already priced in this worst-case scenario.